Although blocking either PD-L1 or PD-1 should similarly inhibit their molecular interaction, it is conceivable that, at least in some anti-PD-L1-treated patients, unblocked PD-L2 activity on PD-1 receptor can still inhibit anti-tumor response. Here, PDCD1 is linked to neoplasm.